The European Medicines Agency (EMA) has accepted AstraZeneca Plc's (NASDAQ:AZN) marketing authorization application for sipavibart for pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients. AstraZeneca's application for sipavibart has been accepted under an accelerated assessment procedure. Also Read: AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion. Sipavibart is an investigational long-acting antibody designed to provide COVID-19
"The EMA's (European Medicines Agency) Committee for Medicinal Products for Human Use(CHMP) granted sipavibart accelerated assessment as it was deemed of major interest for public health and therapeutic innovation," the Anglo-Swedish drugmaker said. An accelerated assessment aims to speed up the EMA's review of a market authorisation application. AstraZeneca acquired sipavibart from RQ Bio in May 2022.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.